The Dementia Discovery Fund (DDF) is a specialist venture capital fund that invests in novel science to create meaningful new medicines for dementia and deliver an attractive return for the fund investors. The founders and investors are a unique blend of Pharma, Government, Charity and significant public/private investors. Collectively they provide value beyond their financial support through network expansion as well as provision of expertise, information and know-how that will increase the probability of success for DDF investments. The DDF will start new projects and companies as part of its working approach as well as source new investments from existing entrepreneurs and across academia, research institutes, universities and the biotech/pharma sector.
DDF U.S. Discovery, Inc. (DUS) is an incubator for building new companies focused on approaches that go beyond the existing dementia treatment hypotheses. These companies will arise from projects seed-funded by DDF. The projects are carried out in collaboration with academic labs and contract research organizations in the following areas: membrane trafficking, microglial biology and neuroinflammation, DNA damage response, and Alzheimer’s Disease target discovery. Unusually, these projects are not centered around a particular academic or lab, but instead focus on rich areas of biology which have been poorly explored for the treatment of dementia.